Anavex Life Sciences Corp (AVXL)

[speramus]

I agree, logic suggest there would be a limited improvement in the PLUS component since we know what the typical impact is of donepezil alone. Correct me if I am wrong but it slows progression in some, delays institutional placement but can't reverse the damage/ or on going damage because it is only affecting acetylcholine concentration, not the underlying cause (which is not truly understood). There are many examples of drugs having a synergistic effect and there may be some positive effect of a PLUS regime in some patients but the study is probably too small and brief to sort it out. IMO AVXL is focusing on establishing efficacy, safety and ultimately approval. Clearly a successful treatment is needed early in development of the disease, just look at the PET images of AD brains and it seems donepezil is like applying a bandage to a cut, damage often significant before any treatment attempt. I thought it would be much more difficult to get approval if Anavex 2-73 has to ride the shoulders of donepezil, JMO. Thanks for your thoughts.